Management of bladder cancer provides a single, comprehensive reference source that incorporates all the latest information regarding bladder cancer. The text covers epidemiology and natural history of bladder cancer as well as latest findings regarding the genetics and molecular biology of the disease. Diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer is discussed. The text incorporates chapters summarizing new findings regarding markers for the diagnosis of bladder cancer and new diagnostic techniques to enhance traditional methods such as cystoscopy. Risk stratified treatment of non muscle invasive bladder cancer including various approaches to intravesical therapy are reviewed. Current guideline based approaches to management and new data regarding diagnosis and prognostication of muscle invasive bladder cancer is analyzed and summarized. The application of chemotherapy for muscle invasive and advanced disease is discussed and the evidence based application of multimodality therapy highlighted. Finally, gaps in current knowledge and areas for future research are highlighted. Ongoing important clinical trials which could imminently yield significant new knowledge is discussed. Authored by experts in their respective fields, Management of Bladder Cancer will serve as a easy and complete reference source for clinicians, researchers, individuals in training, allied health professionals and medical students in the fields of Urology, Medical Oncology, Radiation Oncology, Basic and Translational Science and Epidemiology.
This book presents state-of-the-art diagnoses and treatments available for bladder cancer that has metastasised into the body.
However, HAL (marketed as Hexvix/Cyview by Photocure, Norway) is the only agent approved in both the United States (FDA approved in 2010) and Europe (2005), so we will center our discussion on this formulation. mucosal folds [17], ...
This major urologic malignancy was one of the first cancers to be linked to occupational and environmental exposure to carcinogens. Bladder cancer is the 5th most common cancer of American men and the 8th most common c
McInnes MD, Siemens DR, Mackillop WJ, Peng Y, Wei 132 16 A Systematic Review on the Staging Conundrum in Bladder Cancer 16.1.9 Grey Literature Related to Systematic Review 16.1.10 Systematic Review Conclusion References.
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
Both drug therapies and the range of surgical options are covered, ensuring that this is the perfect tool for clinicians to consult when considering which type of management program is appropriate for each individual patient.
This book covers the latest advances in non-muscle invasive bladder cancer care.
The book features: • Epidemiology, bladder carcinogenesis and divergent molecular pathways of bladder cancer development. • Pathology of bladder tumors, cystoscopy, cytology and newer techniques of bladder cancer diagnosis. • ...
This book presents the substantial academic developments in the field of bladder cancer in one convenient reference.
When are they best used? What is the optimal sequence of treatments for individual patients? This third edition of 'Fast Facts: Bladder Cancer' has been updated extensively throughout by two new authors, bringing a fresh perspective.